Salary Survey: A Healthy Trajectory for Clinical Research Professionals
The perfect storm of industry growth, opportunity, and demand is translating to solid salary and satisfaction levels among clinical trial professionals, according to new survey.
Gene Testing: Future Problem or Just a Blip?
Trial participants are willing to share data to improve their lives and the lives of others, but they also request that data and clinical trial results are shared back to them.
Is Retraining on Good Clinical Practice Guidelines Effective?
Survey results from Clinical Research Malaysia’s GCP refresher workshop.
Back to Basics? Physician Awareness and Nucleic Acid-Based Therapies
Survey data finds that physicians aren’t very familiar with the intricacies of nucleic acid-based therapies.
FDA Cites Expedited Programs in Boosting Review Process
Gains in FDA approval of new drugs and biologics last year are based on limited clinical trials and accelerated review programs.
The Benefits of Advanced Imaging Management Systems
How new technology can impact cardiac imaging in oncology clinical trials and have broader implications for patient safety.
Trial Non-Reporting a European as Well as U.S. Problem
Social media uses transparency to highlight alleged gaps in clinical trial transparency and offers a more powerful approach to health campaigners.
Applied Clinical Trials, January/February 2020 Issue (PDF)
Click the title above to open the Applied Clinical Trials January/February 2020 issue in an interactive PDF format.
Emerging Biopharma Find Ways to Persevere Struggles
David Arthur, CEO of Salarius, discusses efficacy, collaborating with nonprofit institutes to obtain funding, and garnering patient support to increase recruitment in clinical trials.
Technology’s Role in Managing a Compassionate Use Program
ViiV Healthcare outlines techniques and tips for implementing a technology-based process for handling compassionate use requests.
News Notes
A compilation of recently released news briefs that pertain to the clinical trials industry.